Bio-Rad Laboratories, Inc.

Good afternoon. Thank you for attending today's BioBRADS second quarter 2022 earnings results conference call. My name is Hannah and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star 1 on your telephone keypad. I would now like to pass the conference over to our host, Edward Chung, Head of Investor Relations. Please go ahead.

Thanks, operator. Good afternoon, and thank you for joining us. Today, we will review the second quarter 2022 financial results and provide an update on key business trends for Bobcrat. With me on the phone today are Norman Schwartz, our Chief Executive Officer, Alon Baskell, Executive Vice President and Chief Financial Officer, Andy Lapp, Executive Vice President and Chief Operating Officer, Simon May, President of the Life Science Group, and Barbara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management goals, plans and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these four looking statements are commentary regarding the impact of the COVID-19 pandemic on BioRab's results and operations and steps BioRab is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown. You should not place unlimited reliance on these four looking statements. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP net income and eluded earnings per share, which are financial measures that are not defined under generally accepted accounting principles. Investors should review the reconciliation of these non-GAAP measures to the comparable and Chief Financial Officer.

Thank you, Ed. Good afternoon and thank you all for joining us. Before I begin the detailed second quarter discussion, I would like to ask Andy Last, our Chief Operating Officer, to provide an update on BioRed's operations. Andy?